MRFR Research Report Offering Encompasses Different Strategies, Such As Mergers & Acquisitions, Partnerships & Collaborations, Business Expansions, And Product Developments, Adopted By Major Players To Increase Their Neuroblastoma Market Share. Some of the Major Technology Vendors 

Market Highlights

The global Neuroblastoma is anticipated to hold a market value of 2.60 billion in 2017 and is expected to grow at a CAGR of 3.7% during the forecast period.

Neuroblastoma is a childhood cancer most commonly occurs in children below the age of 5 years.

The neuroblast may cause due to the immature cell growth or mutation in the gene responsible for controlling cell proliferation. The increasing cases of childhood cancer, rising research on Neuroblastoma treatment and increasing spending on cancer treatment is expected to drive market growth over the forecast period. According to the American Society of Clinical Oncology (ASCO) April 2018 publication, every year, more than 700 children get diagnosed with Neuroblastoma  in the US and it is also indicated that Neuroblastoma  is the most common cancer in children younger than 1 year. It is more commonly found in boys compare to girls. The increasing cases of childhood cancer boost market growth during the forecast period.

Despite the drivers, shortage of trained healthcare specialists and the high cost of this therapy can restrain the market growth over the assessment period.

Request to Get Free the Sample Pages At - https://www.marketresearchfuture.com/sample_request/6555

Key Players:

Some of the prominent players in the global Neuroblastoma market are

• United Therapeutics Corp.
• APEIRON Biologics AG
• LUMITOS AG
• NANTGE Healthcare
• Pfizer Inc.
• GL Pharm Tech Corporation
• Aetna Inc
• RxStrategies
• Inc. and others.

Segmentation

The global Neuroblastoma market has been segmented into diagnostics, treatment, and end user.

The market, on the basis of diagnostics, has been segmented into various tests, MIBG scan, imaging, and biopsy. The tests are further sub-segmented into bone marrow, tissue, urine, and blood.

The market, by treatment, has been segmented into surgery, chemotherapy, radiation therapy, stem cell transplant, immunotherapy, and monoclonal antibody treatment.

On the basis of end user, the global Neuroblastoma market has been segmented into hospitals ambulatory surgical centers, diagnostic centers, research centers, and others.